Key result
Long-term, high-dose treatment with the ergot-derived dopamine agonists bromocriptine and cabergoline resulted in the development of symptomatic severe mitral regurgitation requiring valve replacement.
Case Report (n=1)
Long-term, high-dose use of ergot-derived dopamine agonists like bromocriptine and cabergoline can cause severe, symptomatic fibrotic valvular heart disease requiring surgical replacement.
Bromocriptine and cabergoline, ergot derived dopamine receptor agonists used to treat Parkinson's disease and prolactinomas, have been associated with increased risk of cardiac valve disease. Here we present a case of iatrogenic symptomatic severe mitral regurgitation due to these drugs.
No takes yet. Share an insight, caveat, or question.
D’Aloia et al. (2015) conducted a case report in Prolactin-secreting pituitary adenoma (n=1). Bromocriptine and Cabergoline was evaluated on Development of severe mitral regurgitation. Long-term, high-dose treatment with the ergot-derived dopamine agonists bromocriptine and cabergoline resulted in the development of symptomatic severe mitral regurgitation requiring valve replacement.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: